- Semaglutide approved for New indication in the treatment of steatohepatitis: According to the announcement made by Novo Nord on August 15th, the US FDA has accelerated the approval of a new indication for the reduced version of semaglutide (trade name Novo Ying) for the treatment of severe steatohepatitis (MASH) related to metabolic dysfunction. Studies have shown that when combined with a balanced diet and exercise, it can improve the organ conditions of patients with fatty liver and moderate to severe liver fibrosis.
- Trends in Biochemical Sciences publishes a special issue on peptide biochemistry: On June 15th, the special issue focuses on peptide therapeutic drugs, ribosome synthesis and post-translational modified peptides (RiPPs), peptide hormones, etc. This paper takes semaglutide, MK-0616, etc. as examples to explore the methods for improving the pharmacokinetic performance and efficacy of peptide drugs, and also mentions the research directions such as optimizing the physicochemical properties of RiPPs through synthetic pathway engineering.
A new breakthrough has been made in electrochemical peptide modification technology: According to a report on Sciencenet on May 21st, the team led by Professor Zhixiong Ruan and Associate Professor Xinwei Hu from Guangzhou Medical University has achieved efficient regioselective diazotization of dehydroalanine peptides. It provides a new approach for the modification of complex bioactive molecules, with a maximum yield of up to 99% and potential for gram-level synthesis, which is conducive to industrial application.
Post time: Aug-20-2025